{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:37Z","timestamp":1787021017957,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are no prior studies investigating the attitudes and knowledge of opioid treatment program (OTP) clinicians on prescribed medicinal cannabis in OTP clients. This study examined the OTP clinicians' medicinal cannabis experience, knowledge, concerns, and educational needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Staff from six public OTP services in New South Wales completed a medicinal cannabis survey. Staff included nurses, doctors, pharmacists, allied health, and consumer workers. Single-level regression models were used to estimate participants\u2019 sex, role, and year of experience effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>102 (63%) clinicians responded to the medicinal cannabis part of the survey, mostly female (n\u2009=\u200958, 56.9%), and more than half worked full-time (n\u2009=\u200954, 52.9%). Most of the participants (88.5%, 85\/96) lacked experience providing medicinal cannabis, two in three (66.7%, 68\/102) agreed to consider medicinal cannabis as a treatment for addressing cannabis use in OTP clients. Over 70% (71.5%, 73\/102) expressed similar agreement to consider medicinal cannabis for other health conditions in OTP clients. More than half of the clinicians (54.2%, 52\/96) expressed a lack of confidence in assisting clients with accessing medicinal cannabis, and were unfamiliar with current regulations (56.2%, 54\/96). Clinicians expressed safety concerns regarding side effects such as driving-related problems (74%, 71\/96), cognitive impairment (54.2%, 52\/96), and cannabis dependence (54.2%, 52\/96). The three conditions most endorsed as having sufficient evidence to support the use of tetrahydrocannabinol (THC)-based medicinal cannabis were palliative care symptom management (72.4%, 71\/98), chronic pain (67.4%, 66\/98), and multiple sclerosis (43.8%, 43\/98). The three conditions most identified as having sufficient evidence to support the routine clinical use of cannabidiol (CBD)-based medicinal cannabis were chronic pain (64.9%, 63\/97), palliative care (62.5%, 60\/96), and sleep problems (44.8%, 43\/96). The most common educational needs identified by participants were the evidence for the effectiveness of medicinal cannabis in cannabis dependence treatment (88.5%, 85\/96), other health conditions (87.5%, 84\/96), and indications and contraindications for using medicinal cannabis (87.5%, 84\/96).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the interest in using medicinal cannabis for treating cannabis dependence and \/or other health conditions, clinicians identified several barriers including limited experience, lack of confidence, and poor understanding of the regulatory framework.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-025-00315-6","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T06:10:03Z","timestamp":1755324603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinicians\u2019 attitudes and knowledge of medicinal cannabis in opioid dependence treatment clinics in New South Wales, Australia"],"prefix":"10.1186","volume":"7","author":[{"given":"Laila","family":"Parvaresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llewellyn","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaleh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tremonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"315_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.euroneuro.2020.03.002","volume":"36","author":"S Babalonis","year":"2020","unstructured":"Babalonis S, Walsh SL. Therapeutic potential of opioid\/cannabinoid combinations in humans: Review of the evidence. Eur Neuropsychopharmacol. 2020;36:206\u201316.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"315_CR2","first-page":"203","volume":"5","author":"YPS Balhara","year":"2014","unstructured":"Balhara YPS. Jain RJJoP, Pharmacotherapeutics. Cannabis Use among Opioid-Dependent Individuals on Opioid Substitution Therapy. 2014;5(3):203\u20135.","journal-title":"Cannabis Use among Opioid-Dependent Individuals on Opioid Substitution Therapy"},{"key":"315_CR3","doi-asserted-by":"crossref","unstructured":"Bawa Z, McCartney D, Manocha R, McGregor ISJBPC. Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021\u20132022 survey. 2022;23(1):330.","DOI":"10.1186\/s12875-022-01946-x"},{"key":"315_CR4","doi-asserted-by":"crossref","unstructured":"Bawor M, Dennis BB, Varenbut M, Daiter J, Marsh DC, Plater C, et al. Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. 2015;6:1\u201311.","DOI":"10.1186\/s13293-015-0038-6"},{"issue":"4","key":"315_CR5","first-page":"8","volume":"7","author":"A Bahji","year":"2016","unstructured":"Bahji A, Mazhar MN. Treatment of cannabis dependence with synthetic cannabinoids: A systematic review. Canadian Journal of Addiction. 2016;7(4):8\u201313.","journal-title":"Canadian Journal of Addiction"},{"issue":"1","key":"315_CR6","first-page":"90","volume":"4","author":"D Bega","year":"2017","unstructured":"Bega D, Simuni T, Okun MS, Chen X. Schmidt PJMdcp. Medicinal Cannabis for Parkinson\u2019s Disease: Practices, Beliefs, and Attitudes among Providers at National Parkinson Foundation Centers of Excellence. 2017;4(1):90\u20135.","journal-title":"Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes among Providers at National Parkinson Foundation Centers of Excellence"},{"issue":"8","key":"315_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.31128\/AJGP-04-21-5936","volume":"51","author":"M Berger","year":"2022","unstructured":"Berger M, Amminger GP, McGregor IS. Medicinal cannabis for the treatment of anxiety disorders. Australian Journal of General Practice. 2022;51(8):586\u201392.","journal-title":"Australian Journal of General Practice"},{"key":"315_CR8","doi-asserted-by":"crossref","unstructured":"Benson MJ, Abelev SV, Corte CJ, Connor SJ, McGregor ISJCs, 360 C. Attitudes and knowledge of Australian gastroenterologists around the use of medicinal cannabis for inflammatory bowel disease. 2020;2(2):otaa045.","DOI":"10.1093\/crocol\/otaa045"},{"issue":"4","key":"315_CR9","first-page":"493","volume":"93","author":"AJ Budney","year":"1998","unstructured":"Budney AJ, Bickel WK, Amass LJA. Marijuana Use and Treatment Outcome among Opioid-Dependent Patients. 1998;93(4):493\u2013503.","journal-title":"Marijuana Use and Treatment Outcome among Opioid-Dependent Patients"},{"issue":"1","key":"315_CR10","first-page":"85","volume":"34","author":"BH Carlini","year":"2017","unstructured":"Carlini BH, Garrett SB. Carter GTJAJoH, Medicine\u00ae P. Medicinal Cannabis: a Survey among Health Care Providers in Washington State. 2017;34(1):85\u201391.","journal-title":"Medicinal Cannabis: a Survey among Health Care Providers in Washington State"},{"key":"315_CR11","unstructured":"Centre for Alcohol and Other Drugs. NSW Clinical Guidelines Opioid Dependence. 2018."},{"key":"315_CR12","unstructured":"Centre for Alcohol and Other Drugs, Ministry of Health, NSW Health. Drug and Alcohol Clinical Research and Improvement Network (DACRIN) 2023 [Available from: https:\/\/www.health.nsw.gov.au\/aod\/dacrin\/Pages\/default.aspx."},{"issue":"3","key":"315_CR13","first-page":"261","volume":"40","author":"K Chandiok","year":"2021","unstructured":"Chandiok K, Marathe S, Rooney M, Stocker J, Tellis B. Pit SJAJoA. Cannabis and Its Therapeutic Value in the Ageing Population: Attitudes of Health-Care Providers. 2021;40(3):261\u201374.","journal-title":"Cannabis and Its Therapeutic Value in the Ageing Population: Attitudes of Health-Care Providers"},{"issue":"1","key":"315_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/j.pain.0000000000002011","volume":"162","author":"J Delorme","year":"2021","unstructured":"Delorme J, Bertin C, Delage N, Eschalier A, Ardid D, Authier N, et al. Prevalence of chronic pain in opioid-maintained patients using the capture\u2013recapture method: a nationwide population-based study. Pain. 2021;162(1):195\u2013202.","journal-title":"Pain"},{"key":"315_CR15","doi-asserted-by":"crossref","unstructured":"Dobson O, Barber M, Graham M, Carter A, Savic MJD, Review A. \u2018The wild west of medicine\u2019: A qualitative investigation of the factors influencing Australian health\u2010care practitioners' delivery of medicinal cannabis. 2024.","DOI":"10.1111\/dar.13847"},{"issue":"5","key":"315_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1055\/s-2002-32713","volume":"29","author":"A Frei","year":"2002","unstructured":"Frei A, Rehm J. The prevalence of psychiatric co-morbidity among opioid addicts. Psychiatr Prax. 2002;29(5):258\u201362.","journal-title":"Psychiatr Prax"},{"key":"315_CR17","doi-asserted-by":"crossref","unstructured":"Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LMJPO. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis\u2013a systematic review. 2019;14(5):e0216556.","DOI":"10.1371\/journal.pone.0216556"},{"key":"315_CR18","unstructured":"Guide DS. Midpoint Recording [Available from: https:\/\/the.datastory.guide\/hc\/en-us\/articles\/360003542256-Midpoint-Recoding"},{"key":"315_CR19","doi-asserted-by":"crossref","unstructured":"Hallinan CM, Gunn JM, Bonomo YAJBo. Implementation of medicinal cannabis in Australia: innovation or upheaval? Perspectives from physicians as key informants, a qualitative analysis. 2021;11(10):e054044.","DOI":"10.1136\/bmjopen-2021-054044"},{"key":"315_CR20","unstructured":"Hewa-Gamage D, Blaschke S, Drosdowsky A, Koproski T, Braun A, Ellen SJJol, et al. A Cross-sectional Survey of Health Professionals' Attitudes toward Medicinal Cannabis Use as Part of Cancer Management. 2019;26(4):815\u201324."},{"key":"315_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108652","volume":"221","author":"M Hordowicz","year":"2021","unstructured":"Hordowicz M, Klimkiewicz A, Jarosz J, Wysocka M, Jastrz\u0119bska MJD, Dependence A. Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature review. Drug and Alcohol Depend. 2021;221: 108652.","journal-title":"Drug and Alcohol Depend"},{"key":"315_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2017.03.006","volume":"77","author":"Y-I Hser","year":"2017","unstructured":"Hser Y-I, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"315_CR23","first-page":"80","volume":"27","author":"NI Jacobs","year":"2019","unstructured":"Jacobs NI, Montebello M, Monds LA, Lintzeris NJAP. Survey of Australian Psychiatrists\u2019 and Psychiatry Trainees\u2019 Knowledge about and Attitudes towards Medicinal Cannabinoids. 2019;27(1):80\u20135.","journal-title":"Survey of Australian Psychiatrists\u2019 and Psychiatry Trainees\u2019 Knowledge about and Attitudes towards Medicinal Cannabinoids"},{"issue":"2","key":"315_CR24","first-page":"84","volume":"8","author":"H Khazaie","year":"2016","unstructured":"Khazaie H, Najafi F, Ghadami MR, Azami A, Nasouri M, Tahmasian M, et al. Sleep disorders in methadone maintenance treatment volunteers and opium-dependent patients. Addict Health. 2016;8(2):84.","journal-title":"Addict Health"},{"key":"315_CR25","volume":"82","author":"S Lake","year":"2020","unstructured":"Lake S. Pierre MSJCPR. The Relationship between Cannabis Use and Patient Outcomes in Medication-Based Treatment of Opioid Use Disorder: A Systematic Review. 2020;82: 101939.","journal-title":"The Relationship between Cannabis Use and Patient Outcomes in Medication-Based Treatment of Opioid Use Disorder: A Systematic Review"},{"issue":"4","key":"315_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/ajad.13153","volume":"30","author":"ZEH Latif","year":"2021","unstructured":"Latif ZEH, Skj\u00e6rv\u00f8 I, Solli KK, Tanum L. Chronic pain among patients with an opioid use disorder. Am J Addict. 2021;30(4):366\u201375.","journal-title":"Am J Addict"},{"key":"315_CR27","doi-asserted-by":"crossref","unstructured":"Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJJMJoA. Medicinal cannabis in Australia, 2016: the cannabis as medicine survey (CAMS\u201016). 2018;209(5):211\u20136.","DOI":"10.5694\/mja17.01247"},{"issue":"1","key":"315_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-022-00666-w","volume":"19","author":"N Lintzeris","year":"2022","unstructured":"Lintzeris N, Mills L, Abelev SV, Suraev A, Arnold JC, McGregor IS. Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduct J. 2022;19(1):88.","journal-title":"Harm Reduct J"},{"key":"315_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.729800","volume":"12","author":"EL Martin","year":"2021","unstructured":"Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, et al. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psych. 2021;12: 729800.","journal-title":"Front Psych"},{"key":"315_CR30","doi-asserted-by":"crossref","unstructured":"Martell BA, o\u2019Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. 2007;146(2):116\u201327.","DOI":"10.7326\/0003-4819-146-2-200701160-00006"},{"key":"315_CR31","volume":"13","author":"SL MacPhail","year":"2022","unstructured":"MacPhail SL, Bedoya-P\u00e9rez MA, Cohen R, Kotsirilos V, McGregor IS. Cairns EAJFiP. Medicinal Cannabis Prescribing in Australia: an Analysis of Trends over the First Five Years. 2022;13: 885655.","journal-title":"Medicinal Cannabis Prescribing in Australia: an Analysis of Trends over the First Five Years"},{"key":"315_CR32","doi-asserted-by":"publisher","unstructured":"Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database of Sys Rev. 2019;2019(1):CD008940. https:\/\/doi.org\/10.1002\/14651858.CD008940.pub3.","DOI":"10.1002\/14651858.CD008940.pub3"},{"key":"315_CR33","unstructured":"NSW Health. Clinical guidance for cannabis medicine prescribers 2023 [Available from: https:\/\/www.health.nsw.gov.au\/pharmaceutical\/Pages\/nsw-cmas.aspx."},{"key":"315_CR34","unstructured":"NSW Health. Medication Handling, PD2022_032 2022 [Available from: https:\/\/www1.health.nsw.gov.au\/pds\/Pages\/doc.aspx?dn=PD2022_032."},{"key":"315_CR35","unstructured":"Organization WH. The health and social effects of nonmedical cannabis use. 2016."},{"key":"315_CR36","doi-asserted-by":"publisher","unstructured":"O\u2019Rourke R, Lima ML, Jetten J.JJoPH. Healthcare professionals and medical cannabis: a scoping review informed by the theoretical domains framework. 2022:1\u201313. https:\/\/doi.org\/10.1007\/s10389-021-01624-9.","DOI":"10.1007\/s10389-021-01624-9"},{"issue":"9","key":"315_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/medicina55090525","volume":"55","author":"L Orsolini","year":"2019","unstructured":"Orsolini L, Chiappini S, Volpe U, De Berardis D, Latini R, Papanti GD, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina. 2019;55(9):525.","journal-title":"Medicina"},{"key":"315_CR38","doi-asserted-by":"crossref","unstructured":"Parvaresh L, Mills L, Gholami J, Jansen L, Jamshidi N, Baker K, et al. Clinicians\u2019 perspectives on cannabis use and cannabis treatment in clients undertaking Opioid Dependence Treatment 2024.","DOI":"10.1111\/dar.14074"},{"key":"315_CR39","unstructured":"Pavanetti GGL, Amantini CV, Medina DDD, dos Santos IO, Oliveira JPB, Ribeiro KN, et al. The use of medicinal cannabis as an alternative treatment for depressive disorders: integrative review. 2024."},{"issue":"10","key":"315_CR40","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/add.14234","volume":"113","author":"A Peacock","year":"2018","unstructured":"Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113(10):1905\u201326.","journal-title":"Addiction"},{"key":"315_CR41","first-page":"1","volume":"20","author":"LM Philpot","year":"2019","unstructured":"Philpot LM, Ebbert JO. Hurt RTJBFp. A Survey of the Attitudes, Beliefs and Knowledge about Medical Cannabis among Primary Care Providers. 2019;20:1\u20137.","journal-title":"A Survey of the Attitudes, Beliefs and Knowledge about Medical Cannabis among Primary Care Providers"},{"key":"315_CR42","doi-asserted-by":"crossref","unstructured":"R\u00f8nne ST, Rosenb\u00e6k F, Pedersen LB, Waldorff FB, Nielsen JB, Riisgaard H, et al. Physicians\u2019 experiences, attitudes, and beliefs towards medical cannabis: a systematic. BMC Family practice,. 2021.","DOI":"10.21203\/rs.3.rs-397404\/v1"},{"issue":"8","key":"315_CR43","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/j.1526-4637.2009.00726.x","volume":"10","author":"GM Reisfield","year":"2009","unstructured":"Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 2009;10(8):1434\u201341.","journal-title":"Pain Med"},{"key":"315_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109551","volume":"238","author":"T Santo Jr","year":"2022","unstructured":"Santo T Jr, Campbell G, Gisev N, Martino-Burke D, Wilson J, Colledge-Frisby S, et al. Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. Drug Alcohol Depend. 2022b;238: 109551.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"315_CR45","first-page":"979","volume":"78","author":"T Santo","year":"2021","unstructured":"Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of Opioid Agonist Treatment with All-Cause Mortality and Specific Causes of Death among People with Opioid Dependence: a Systematic Review and Meta-Analysis. 2021;78(9):979\u201393.","journal-title":"Association of Opioid Agonist Treatment with All-Cause Mortality and Specific Causes of Death among People with Opioid Dependence: a Systematic Review and Meta-Analysis"},{"key":"315_CR46","volume":"238","author":"T Santo Jr","year":"2022","unstructured":"Santo T Jr, Campbell G, Gisev N, Martino-Burke D, Wilson J, Colledge-Frisby S, et al. Prevalence of Mental Disorders among People with Opioid Use Disorder: A Systematic Review and Meta-Analysis. 2022a;238: 109551.","journal-title":"Prevalence of Mental Disorders among People with Opioid Use Disorder: A Systematic Review and Meta-Analysis"},{"issue":"1","key":"315_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/10550880802545101","volume":"28","author":"RA Sansone","year":"2009","unstructured":"Sansone RA, Whitecar P, Wiederman MW. The prevalence of childhood trauma among those seeking buprenorphine treatment. J Addict Dis. 2009;28(1):64\u20137.","journal-title":"J Addict Dis"},{"issue":"1\u20132","key":"315_CR48","first-page":"87","volume":"40","author":"HJB Scheff\u00e9","year":"1953","unstructured":"Scheff\u00e9 HJB. A Method for Judging All Contrasts in the Analysis of Variance. 1953;40(1\u20132):87\u2013110.","journal-title":"A Method for Judging All Contrasts in the Analysis of Variance"},{"issue":"3","key":"315_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40501-022-00260-8","volume":"9","author":"SK Stack","year":"2022","unstructured":"Stack SK, Wheate NJ, Schubert EA. Medicinal cannabis for the treatment of anxiety disorders: a narrative review. Current Treatment Options in Psychiatry. 2022;9(3):163\u201373.","journal-title":"Current Treatment Options in Psychiatry"},{"key":"315_CR50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.drugalcdep.2017.07.007","volume":"179","author":"MD Stein","year":"2017","unstructured":"Stein MD, Conti MT, Kenney S, Anderson BJ, Flori JN, Risi MM, et al. Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder. Drug Alcohol Depend. 2017;179:325\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"315_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/YCO.0000000000000566","volume":"33","author":"M Van Ameringen","year":"2020","unstructured":"Van Ameringen M, Zhang J, Patterson B, Turna J. The role of cannabis in treating anxiety: an update. Curr Opin Psychiatry. 2020;33(1):1\u20137.","journal-title":"Curr Opin Psychiatry"},{"key":"315_CR52","first-page":"1","volume":"3","author":"JM Weisman","year":"2021","unstructured":"Weisman JM. Rodr\u00edguez MJJoCR. A Systematic Review of Medical Students\u2019 and Professionals\u2019 Attitudes and Knowledge regarding Medical Cannabis. 2021;3:1\u201320.","journal-title":"A Systematic Review of Medical Students\u2019 and Professionals\u2019 Attitudes and Knowledge regarding Medical Cannabis"},{"issue":"6","key":"315_CR53","first-page":"614","volume":"24","author":"J Wildberger","year":"2019","unstructured":"Wildberger J. Katz ECJJoSU. Attitudes toward Medical Marijuana among Substance Use Clinicians. 2019;24(6):614\u20138.","journal-title":"Attitudes toward Medical Marijuana among Substance Use Clinicians"},{"issue":"3","key":"315_CR54","first-page":"27472","volume":"17","author":"S Yarnell","year":"2015","unstructured":"Yarnell S. The use of medicinal marijuana for posttraumatic stress disorder: A review of the current literature. The Primary Care Companion for CNS Disorders. 2015;17(3):27472.","journal-title":"The Primary Care Companion for CNS Disorders"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-025-00315-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-025-00315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:50:58Z","timestamp":1757429458000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-025-00315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1186\/s42238-025-00315-6","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects provided their informed consent for inclusion in the study before completing the survey. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Sydney University Human Research Ethics Committee (X22-0327 & 2022\/ETH01545).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}